VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH UNCONTROLLED ARTERIAL HYPERTENSION - ENDOTHELIN-2
Phase 2 – studying effectiveness and dosage
Conditions:
Uncontrolled arterial hypertension
Sponsor: Centre Hospitalier Universitaire Rouen
trial.available_in:
БГ
Overview
Trial status: Authorised
8 week change in peripheral and central arterial pressures and arterial stiffness, 8-week change in local concentrations of NO, EETs and ET-1 with sustained increase in blood flow, Variation in 8 weeks of natriuresis and measured glomerular filtration rate (DTPA labeled by the technetium 99m)
8-week change in amplitude of endothelium-dependent radial artery dilatation with sustained increase in blood flow
Description
8 week change in peripheral and central arterial pressures and arterial stiffness, 8-week change in local concentrations of NO, EETs and ET-1 with sustained increase in blood flow, Variation in 8 weeks of natriuresis and measured glomerular filtration rate (DTPA labeled by the technetium 99m)
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 24 participants
БГ